Table: q1_q4_2019_prescription_drugs_wac_increases , manufacturer_name like J*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id	manufacturer_name	date_reported	ndc_number	drug_product_description	wac_effective_date	wac_increase_amount	wac_after_increase	patent_expiration_date	drug_source_type	unit_sales_volume_in_us	unit_sales_volume_non_public_indicator	cost_increase_factors	cost_increase_factors_non_public_indicator	change_improvement_description	change_improvement_non_public_indicator	acquisition_date	company_acquired_from	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	wac_at_acquisition	wac_year_prior_to_acquisition	year_drug_introduced_to_market	wac_at_intro_to_market	supporting_documents	general_comments
Rx0000008	Jazz Pharmaceuticals, Inc.	03/31/2019	68727010001	Xyrem	01/04/2019	302.08	4617.44	09/15/2033	Single Source Drug	1404866000	None	None	1	A change or improvement to the drug did not necessitate the price increase	None	None	None	None	None	None	None	None	None	None	None	The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 30, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. The drug was not was acquired from another manufacturer within the last five years.
Rx0000008	Jazz Pharmaceuticals, Inc.	09/30/2019	68727010001	Xyrem 500 MG/ML Oral Solution 180 ml	07/10/2019	92.35	4709.79	09/15/2033	Single Source Drug	1404866000	None	None	1	A change or improvement to the drug did not necessitate the price increase	None	None	None	None	None	None	None	None	None	None	None	The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 30, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. The drug was not was acquired from another manufacturer within the last five years.